Table 4. Indirect effects - herd protection and serotype replacement.^a.

	Dutch data8	UK data6
Percentage change in non-VT IPD, for age group:
< 2 y	1.37 (0.77;2.46)	1.68 (1.37;2.06)
2–4 y	1.22 (0.47;3.18)	1.82 (1.30;2.55)
5–14 y	1.58 (0.77;3.26)	0.82 (0.64;1.04)
15–44 y	1.22 (0.96;1.54)	0.85 (0.71;1.02)
45–64 y	1.37 (1.11;1.70)	0.96 (0.87;1.06)
65+ year	1.25 (1.09;1.43)	1.48 (1.32;1.65)
Percentage change in VT IPD, for age group:
< 2 y	0.01 (0.01;0.02)b	0.02 (0.01;0.05)
2–4 y	0.19 (0.06;0.66)	0.07 (0.04;0.13)
5–14 y	0.36 (0.12;1.14)	0.25 (0.16;0.38)
15–44 y	0.81 (0.59;1.29)	0.12 (0.07;0.21)
45–64 y	0.46 (0.33;0.63)	0.15 (0.12;0.18)
65+ year	0.45 (0.37;0.55)	0.19 (0.14;0.25)

^a Mean and confidence interval; IPD, invasive pneumococcal disease; VT, Vaccine-type; ^b No change in VT IPD in the original data; a continuity correction of 0.5 was applied, with an assumed confidence interval of Exp(ln(0.01)*1.1) to Exp(ln(0.01)*0.9).